Jennison Associates
VERV

Jennison Associates’s Verve Therapeutics VERV Stock Holding History

Jennison Associates’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-448,765
Closed -$16.5M – 711
2021
Q4 		$16.5M Buy
448,765
+83,188
+23% +$3.49M 0.01% 395
2021
Q3 		$17.2M Sell
365,577
-4,423
-1% -$260K 0.01% 386
2021
Q2 		$22.3M Buy
+370,000
New +$15.4M 0.01% 357

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Jennison Associates's VERV Position: Q1 2022 in Review

Jennison Associates sold out of Verve Therapeutics (VERV) in Q1 2022, closing a stake of 448,765 shares — an estimated $16.5M sold.

Jennison Associates first reported a position in VERV in Q2 2021 and held it in 3 quarters. The position peaked at $22.3M in Q2 2021. 92 funds tracked by Wall St. Rank hold VERV as of Q1 2022.

  • Jennison Associates reported no remaining Verve Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 448,765 Verve Therapeutics shares in Q1 2022, an estimated $16.5M.
  • Jennison Associates first reported a position in Verve Therapeutics in Q2 2021 and held it in 3 quarters.
  • Jennison Associates's Verve Therapeutics position peaked at $22.3M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.